What Is Cerebrolysin? A Neuropeptide Research Overview

Cerebrolysin is a peptide preparation derived from purified porcine (pig) brain proteins, consisting of low-molecular-weight neuropeptides and free amino acids. It is studied in neurological and neurodegeneration research as a proposed neurotrophic agent — a substance investigated for its ability to mimic the activity of the brain’s own nerve-growth signals. This article is educational only. Bolt Peptide does not sell Cerebrolysin, and any research materials referenced are intended strictly for laboratory research use only (RUO) — not for human or veterinary use.

Quick facts

• Class: brain-derived neuropeptide preparation (porcine origin)
• Research focus: neurotrophic-factor-like activity and neuroprotection research
• Composition: a heterogeneous mixture of short peptides (generally ≤ 10,000 daltons) and free L-amino acids
• Regulatory status: not approved by the U.S. FDA for any use

What is Cerebrolysin?

Cerebrolysin is produced by the controlled enzymatic breakdown of purified porcine brain proteins, yielding a defined mixture of free amino acids and biologically active low-molecular-weight peptides. Because these fragments are small, much of the research literature has focused on whether they can interact with the central nervous system in ways that resemble the body’s endogenous neurotrophic factors. In the scientific literature it is most often described as a peptide preparation with proposed neurotrophic and neuroprotective properties, and it is studied as a model compound in neurodegeneration and neurorecovery research rather than as a single, isolated molecule.

What does the research show?

Cerebrolysin has been examined in a substantial body of clinical-trial literature, and findings are mixed. A 2009 review in Drugs & Aging summarized randomized trials in Alzheimer-type and vascular dementia, reporting improvements on cognitive and global outcome measures versus placebo in studies up to roughly 28 weeks (Plosker & Gauthier, 2009). In the stroke-research setting, a 2025 systematic review and meta-analysis of 14 randomized controlled trials reported a statistically significant mean improvement on a neurological-deficit scale, while functional-independence measures showed only favorable trends (Patel et al., 2025). Other syntheses have been more cautious: a 2017 meta-analysis of seven randomized trials concluded that the available evidence did not support routine use for long-term stroke rehabilitation (Zhang et al., 2017). Taken together, the literature reflects an active but unsettled research area, and these findings are attributed to the cited studies — they are not claims about outcomes for any individual.

Mechanisms studied in the lab

• Neurotrophic-factor-like activity: preclinical work has investigated whether Cerebrolysin’s peptide fragments can mimic signaling associated with endogenous factors such as BDNF, NGF, and GDNF.
• Neuroprotection in models: laboratory and animal models have examined effects on neuronal survival, synaptic plasticity, and inflammatory signaling under injury or stress conditions.

Research status

Cerebrolysin has been marketed and used clinically in a number of countries outside the United States for several decades and has been evaluated in numerous clinical trials. However, it is not approved by the U.S. Food and Drug Administration for any indication, and no statement here should be read as a representation that it is safe or effective for any human use. Any Cerebrolysin-related material handled in a research context should be treated as a research chemical for laboratory research use only (RUO).

Related research peptides

Researchers studying central-nervous-system (CNS) peptides often compare Cerebrolysin to other compounds in the neuropeptide literature. Browse the full research peptide catalog, or read our educational overviews of two CNS-focused peptides: Semax and Selank.

FAQ

Is Cerebrolysin FDA-approved? No. Cerebrolysin is not approved by the U.S. FDA for any use. It is used clinically in some other countries and has been studied in clinical trials, but in the United States any related material is handled strictly as a research compound (RUO).

What is Cerebrolysin made from? It is a preparation derived from purified porcine (pig) brain proteins, processed into a mixture of free amino acids and low-molecular-weight neuropeptides.

Does Bolt Peptide sell Cerebrolysin? No. This article is educational only. Bolt Peptide does not offer Cerebrolysin for sale.

References

1. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009.
2. Zhang D, et al. Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of RCTs. Biomed Res Int. 2017.

For research use only. Cerebrolysin is not FDA-approved; not for human or veterinary use. Statements have not been evaluated by the FDA.